Survodutide trial overview

Survodutide: an overview of phase 2 trial NCT04667377 — population, study design, reported results and limitations, with the primary citations. Investigational; no dose amounts, cadence or escalation steps are reproduced.

Study design

Randomised, double-blind, placebo-controlled phase 2 trial with four survodutide groups, each assigned a different target, plus placebo. The assignments are in the linked paper and registry record and are not reproduced here.

Population

387 adults aged 18–75 with BMI 27 or higher and without diabetes, at 43 centres in 12 countries; randomised 1:1:1:1:1.

Duration

46 weeks of treatment

Reported results

Planned-treatment mean weight change at week 46 ranged from −6.2% in the lowest-target group to −14.9% in the highest-target group, vs −2.8% with placebo. 233 of 386 treated participants completed treatment; gastrointestinal events affected 75% on survodutide vs 42% on placebo.

Limitations

One phase 2 trial in adults without diabetes. Only 233 of 386 treated participants completed treatment, so the size of the effect depends on how missing data are handled. Phase 3 trials are separate studies and are not combined with this one.

Regulatory context

Investigational. No FDA-approved labeling exists; other countries were not verified.

Sources

Educational use only, never medical advice. No doses.